_1574657156572.png?format=webp&height=120&width=120){kind=logo}
Hansa Biopharma - About the company
Hansa Biopharma is a public company based in Lund (Sweden), founded in 2007. It operates as a Developer of therapeutics to treat rare immunological diseases. Hansa Biopharma has raised an undisclosed amount in funding. The company has 318 active competitors, including 120 funded and 69 that have exited. Its top competitors include companies like Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics.
Company Details
Developer of therapeutics to treat rare immunological diseases. The company is developing and commercializing immunomodulating therapies across transplantation, autoimmune diseases, gene therapy, and oncology indications.
- Website
- hansabiopharma.com
- Email ID
- *****@hansamedical.com
- Phone Number
- +46 **********
- Registered Address
- Scheelevägen 22, SE-220 07 LUND
Key Metrics
Founded Year
2007
Location
Lund, Sweden
Stage
Public
Latest Funding Round
Investors
Ranked
31st among 318 active competitors
Employee Count
149 as on Oct 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Hansa Biopharma
Hansa Biopharma is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
HANSA SALES CIN: 40103812575 , Latvia, Active | Jul 30, 2014 | €0 - €1M (As on Dec 31, 2024) | 1 (As on Dec 31, 2022) | - |
HANSA BIO CIN: 40103899653 , Latvia, Active | May 18, 2015 | €0 - €1M (As on Dec 31, 2024) | 2 (As on Dec 31, 2022) | - |
HANSA BIOPHARMA AB CIN: 925873667 , Norway, Active | Jun 04, 2007 | - | - |
Hansa Biopharma's IPO details
Hansa Biopharma got listed on Oct 19, 2007.
Click here to take a look at Hansa Biopharma's IPO in detail
Sign up to download Hansa Biopharma's company profile
Hansa Biopharma's funding and investors
Hansa Biopharma has raised funding over 4 rounds. Its first funding round was on Nov 29, 2017. Its latest funding round was a Post IPO round on Mar 20, 2026 for $*****. 1 investor participated in its latest round. Hansa Biopharma has 3 institutional investors.
Here is the list of recent funding rounds of Hansa Biopharma:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 20, 2026 | 9312279 | Post IPO | 8997446 | 6688293 | 6118650 | 4728770 |
Jul 19, 2022 | 6102663 | Post IPO | 6887341 | 6333293 | 1632940 | |
Jul 08, 2020 | 1349915 | Post IPO | 4550060 | 5781852 | 3122243 | 9127116 |
Access funding benchmarks and valuations. Sign up today!View details of Hansa Biopharma's funding rounds and investors
Hansa Biopharma's founders and board of directors
Founder? Claim ProfileHansa Biopharma's employee count trend
Hansa Biopharma has 149 employees as of Oct 26. Here is Hansa Biopharma's employee count trend over the years:
Uncover Hansa Biopharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Hansa Biopharma's Competitors and alternates
Top competitors of Hansa Biopharma include Sana Biotechnology, TScan Therapeutics and Viridian Therapeutics. Here is the list of Top 10 competitors of Hansa Biopharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
2nd | _1556184640480.png?devicePixelRatio=2&height=30&width=30){kind=logo} TScan Therapeutics 1995, Boston (United States), Public | Developer of T cell therapies to harness the immune system against cancer | $180M | 70/100 | |
3rd |  Viridian Therapeutics 2007, Boulder (United States), Public | Developer of medicines for patients with serious and rare diseases | $14.5M | 69/100 | |
4th | Autolus 2015, London (United Kingdom), Public | Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 65/100 | |
5th |  Sonoma Biotherapeutics 2012, San Francisco (United States), Series B | Developer of T-cell-based therapies for autoimmune and degenerative diseases | $335M | 64/100 | |
6th | Cue Biopharma 2015, Cambridge (United States), Public | Precision immunotherapies to transform patients' lives by selectively modulating the immune system | $26.4M | 64/100 | |
7th | Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public | Developer of therapeutics for autoimmune diseases | - | 64/100 | |
8th |  Alumis 2003, San Francisco (United States), Public | Developer of therapeutics for the treatment of auto-immune disease | $529M | 63/100 | |
9th | Orca Bio 2016, Menlo Park (United States), Series F | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | $300M | 63/100 | |
10th |  Q32 Bio 2018, Cambridge (United States), Public | Developer of drugs for treating autoimmune disorders | $106M | 63/100 | |
31st | _1574657156572.png?devicePixelRatio=2&height=30&width=30){kind=logo} Hansa Biopharma 2007, Lund (Sweden), Public | Developer of therapeutics to treat rare immunological diseases | - | 60/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Hansa Biopharma's competitors? Click here to see the top ones
Hansa Biopharma's Investments and acquisitions
Hansa Biopharma has acquired 2 companies including Immago Biosystems and Cartela AB. Hansa Biopharma has not made any investments as of now.Reports related to Hansa Biopharma
Here is the latest report on Hansa Biopharma's sector:
News related to Hansa Biopharma
Filter this listMedia has covered Hansa Biopharma for a total of 33 events in the last 1 year, 8 of them have been about company updates and 4 about people movement.
•
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial ResultsPR Newswire•Nov 11, 2026•Hansa Biopharma
•
Hansa Biopharma Partners with Cradle for AI-Driven Protein DesignCision•Oct 01, 2026•Hansa Biopharma, Cradle
•
•
Hansa Biopharma Files Draft Registration Statement for Potential US IPO of ADSsCision•Aug 21, 2026•Hansa Biopharma
•
Hansa Biopharma announces first commercial kidney transplant patGuruFocus•Aug 18, 2026•Hansa Biopharma
•
Hansa Biopharma announces Q2 2026 financial results including a significant out-licensing dealCision•Jul 22, 2026•Hansa Biopharma
•
SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa BiopharmaGlobeNewswire•Jul 01, 2026•Hansa Biopharma, SERB
•
Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for `What's Hot, What's New' Plenary at ATC 2026Stock Screener•Jun 24, 2026•Hansa Biopharma
•
Hansa Biopharma Appoints Adam Cutler as New Chief Financial OfficerCision•Jun 15, 2026•Hansa Biopharma
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Hansa Biopharma
Explore our recently published companies
- Way - Helsinki based, 2024 founded, Seed company
- Delite - Hyderabad based, 2010 founded, Unfunded company
- Yuki - Tel Aviv based, 2023 founded, Seed company
- Hedgepointcapital.com - 2021 founded, Funding Raised company
- MicroRoboTech - Hangzhou based, 2025 founded, Series A company
- Semper Plugins - Durham based, 2011 founded, Acquired company
